{"name":"Peter MacCallum Cancer Centre, Australia","slug":"peter-maccallum-cancer-centre-australia","ticker":"","exchange":"","domain":"petermac.org","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"177Lu-FAP-2286","genericName":"177Lu-FAP-2286","slug":"177lu-fap-2286","indication":"Relapsed or refractory follicular lymphoma","status":"phase_2"},{"name":"Capecitabine Pill","genericName":"Capecitabine Pill","slug":"capecitabine-pill","indication":"Metastatic colorectal cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"68Ga-FAPi-46","genericName":"68Ga-FAPi-46","slug":"68ga-fapi-46","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Azacitidine and eltrombopag","genericName":"Azacitidine and eltrombopag","slug":"azacitidine-and-eltrombopag","indication":"Treatment of myelodysplastic syndromes (MDS), Treatment of low platelet count (thrombocytopenia) in patients with chronic liver disease","status":"phase_2"}]}],"pipeline":[{"name":"177Lu-FAP-2286","genericName":"177Lu-FAP-2286","slug":"177lu-fap-2286","phase":"phase_2","mechanism":"177Lu-FAP-2286 is a radiolabeled antibody that targets folate receptor alpha (FRα) for the treatment of cancer.","indications":["Relapsed or refractory follicular lymphoma","Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"68Ga-FAPi-46","genericName":"68Ga-FAPi-46","slug":"68ga-fapi-46","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Azacitidine and eltrombopag","genericName":"Azacitidine and eltrombopag","slug":"azacitidine-and-eltrombopag","phase":"phase_2","mechanism":"Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes. Eltrombopag is a thrombopoietin receptor agonist that stimulates platelet production.","indications":["Treatment of myelodysplastic syndromes (MDS), Treatment of low platelet count (thrombocytopenia) in patients with chronic liver disease"],"catalyst":""},{"name":"Capecitabine Pill","genericName":"Capecitabine Pill","slug":"capecitabine-pill","phase":"phase_2","mechanism":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","indications":["Metastatic colorectal cancer","Metastatic breast cancer","Gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNVlBBN3BBZXZVUGM3OUZkYzlLY1JYV1VXc2toLTJLam9IRXBuMGE2bUVIMzhLQU83bmI1UmFGcmZ0T2hNSFBfOUZsbE0tSml5T2NaY09WQTlKeVMwaERTZDY1d1V2anl3SUtMSjlqOTRBN3NkVk9YNHJudUFZQ2dwY3F6OUs3MEVEb3FOcEktMGR3OG9lRjMxRUxaYXJIQmgwMFdyOGY1ZE5BbkwtNmZBVVlENWFoVHM0allMUWJadUFFWXJMVjJmY25vb3RmcFN0eDlRTWJJdVNWSTZQTHVwNXRTRjlja2lXbFFnWC1Nb3h6M21SSjdzT1lIZFpROW9HcndCZDZUNTl2SE5leDdIZWhyQlNQQTFm?oc=5","date":"2026-03-30","type":"deal","source":"TradingView","summary":"Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre For Second AI-Driven Drug Synergy Screening Program - TradingView","headline":"Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre For Second AI-Driven Drug Synergy Screening Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQLTE0S010QlRyWDdmdE4wNWdBcHM1QXd2YjVKSm5jYlI1T1U1YUdSNUIyOTNwX1RIZDE0cmVDU2NVYXloUlIyaU5nc3FjaUdjbDl3NlZ3aHQzT0R2c0dEYnZ4cXgwM2xKNTQyX0NuSG9nNlNpa2xneENyWjJnZ3lMRmlud2F0MGxYNHRINnpjTXpNVlRwRV9XVUVaMGt6dURfTE5WUGVZVDRvRFlVWUpPR09GOGNHdFREc1NDRlFJLW9iTkNUWkJpUXY5OHdBaXpsbHZmNzNFcDVyNUlhYmltX3Y0WHJUdXlq?oc=5","date":"2026-03-30","type":"deal","source":"marketscreener.com","summary":"Algorae pharmaceuticals partners with Peter MacCallum Cancer Centre for second AI-driven drug synergy screening program - marketscreener.com","headline":"Algorae pharmaceuticals partners with Peter MacCallum Cancer Centre for second AI-driven drug synergy screening program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPNmN6UklxQUYyYW1pTjhVcjRDd3hQT3Y4TWlKdVBiUVJXZ0t3TFZNbVZlb0pFSU1HMlNoNVJlMDAyVE9IcFBDdzl2cV8wa2lpR1ZMV2FueUpFWHJSN1Fqdjk2emVadDlZendUQTZjSUJnU2tyS0Rhc0E1OGQ4dEVtcS1fLTZvUk1jZE02NEhYTk5kbHYySUJMXzRMUVBpZkxWTjBfaTlPeUkxTlVxRTQ0TUFXSTBpc0VvNVdxS3RTd0ZkNmdlanhhY0VWZGVDZ3d4cnc?oc=5","date":"2026-03-30","type":"pipeline","source":"smallcaps.com.au","summary":"Algorae Pharmaceuticals Enters Second Drug Synergy Screening Program with Peter MacCallum Cancer Centre - smallcaps.com.au","headline":"Algorae Pharmaceuticals Enters Second Drug Synergy Screening Program with Peter MacCallum Cancer Centre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQcGFYNURQdktwN1gzT3N2NWtYRVNocl8xM1J0OXhFWUczNURKc19lVUxwZGFNRlpUc0xzLU9sVmV5cVRva0tWSV95RFM4N0JiRmdHX3ZiQXR5N3hVaW85aFVXVEhfeTZYVWppQl80NG9NV0lQMV82a0ZCYjdMRnhZbQ?oc=5","date":"2026-03-27","type":"pipeline","source":"Mirage News","summary":"Earlier, Faster, And Fairer Access To New Medicines - Mirage News","headline":"Earlier, Faster, And Fairer Access To New Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1DbjVybnZFdHBqWVc5YzVzZnRtTFFZdTByWEZXSF82OWxtSkhkME9LTGRZa0dBTHJjSENoUnk0QVl6bmJfWnBkTTV2MVVhYXkwSlA4Yy1oWGhrVExfeVdJTS1FenpHUDRWSzdPOHliMkptR04zRDJpcw?oc=5","date":"2026-02-17","type":"pipeline","source":"pharmaphorum","summary":"Mark Dawson named head of Roche's pRED unit - pharmaphorum","headline":"Mark Dawson named head of Roche's pRED unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPVDVFelh5TnliQnFXT2JNdlZkNGJDRUhFbm5WNzNlU3lrd3prMkFDbWlNQ0FWZGhmODNoamNuWS1hOXI1cVlFUDJ4WEtYZC1DWHdRWV9UWGdUbnBfNXM0d1NHeE1PS1NHYzRFZXhRQ2NzUnBTNF9Wc0R4NE5Rd05fR2ZHYWE1cndVS25GaUFQNGdZQXZ0bWd1Sl9PTkNYUExPOUhnV3pIdw?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"Prize-winning cancer doctor to steer Roche early drug research - Stock Titan","headline":"Prize-winning cancer doctor to steer Roche early drug research","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-17","type":"pipeline","source":"Indian Pharma Post","summary":"Roche appoints Mark Dawson as new Head of Pharma Research and Early Development - Indian Pharma Post","headline":"Roche appoints Mark Dawson as new Head of Pharma Research and Early Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNQ0dRNlFlWHR4OEtpckI5RU5KUWExMGtKWlFDYWV1MVBuSHg0ZVdTUVhMSGtTV3lONkV0cGhxNUhuZmZpandhVXBIRTNmT1VLTEVzUEhSeGF4anVBV2tLaDlRZDg0ZEFSNzJfZWp3SHlZTUdZX2p6X1dNRlZZWlR4VWJvel94amFlNzdqUmN1Q3hkRU9iY3NUcFJnNlJDSnUxSGFnQ1NwVjhhSGU3RDdhSk9tVVNJeGpvZUN5dlZlb1ZVNXIw?oc=5","date":"2025-12-07","type":"pipeline","source":"Biotech Dispatch","summary":"Algorae Pharmaceuticals achieves milestone with validation of AI drug-combination platform - Biotech Dispatch","headline":"Algorae Pharmaceuticals achieves milestone with validation of AI drug-combination platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQNU5USnFXZ0lTSUhtYld4b04tU3dnUkhUNkxfNTFfRE5RMUN4aTFkYmZLSkloVkcxd2N5Wl9FdHVKWVRUc1BWZnVYZGVOZE9FZU8xcFgyaXA0c0JKMXA2SGhweWh5WkxNYU1FRHk0dWpYdm5iRHl5cW9WZFZ6V3hocl9URkcyYTlSTmJYeUZaSDRleXh1aDZaVmNvS19uSGYycHh2dk80dmZYSktwZ3lnTWkzbmlVNnFzUHN3ZGNEOTBwTklRZk10RHllWEVFQmtC?oc=5","date":"2025-12-04","type":"pipeline","source":"smallcaps.com.au","summary":"Algorae Pharmaceuticals Achieves Independent Validation of AlgoraeOS and Launches Enhanced v2 Platform - smallcaps.com.au","headline":"Algorae Pharmaceuticals Achieves Independent Validation of AlgoraeOS and Launches Enhanced v2 Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQUGs0VWZuWUpPRTRoeEdZSG1CNDlDY3FhYXFWdFRENV9saktKY1R3Um9zMXNIYmoySkZxRUJJSzQ4aWJ2LWlGenVsb180S05YUWw4bE9sRlRjSE5POHhrY05JVVhENUh1MUI3QndhM1RkX3lJTUxsVmU2YmdxZTJSLUh2T2h6X0kwcVpMaFBiNDc3ZlhPLWtENDN1WXhzODlFaW55NGRmSDJXWnNjY1ltLU50N0FGRXFNNERMdnRrYXdVeW5haUxB?oc=5","date":"2024-10-15","type":"pipeline","source":"AFR","summary":"Big pharma takes on doctors over homebrew cancer treatments - AFR","headline":"Big pharma takes on doctors over homebrew cancer treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQTGZLdzN4anluNmlYald0dlBXdGkyR1J6ODBnWHhkY1JibGx3SXNlSWxzVzUzSE4xdERJM3d5bER2RDVkbDl1cGswakpKZ3JtbDFxWUx2b3dld1lVMWR2TEtjQWp5T1I4V1JPb0hMT2E2VUFfRUFpYkJZeDRWZWpUR25PRjBabUdjS1dQVUl0eUp3TlRTTW85cFRYNzNBQ2NZTHJRTFkwdWZlaVd0bmQwZ1FwZGxtclI0cEhhMUJn?oc=5","date":"2023-07-26","type":"pipeline","source":"ASCO Daily News","summary":"Clinical Conundrum: De-Escalating Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer - ASCO Daily News","headline":"Clinical Conundrum: De-Escalating Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUnpscU5sWF94emFvQXpRNkJzeEh5M2Uzd2pQdzZzZzJvWDVrUjgwNmJFWVNTNHVzOE8yY2hnaXY0cXBRLVNLYWFEVE4wMXZ2TzNwcjdVUmZVRVpyWFFuYUo3dWs1TkhrR2JBNVdpYmticFVxcGhpYjN6TnlvY3FJaVJPb2U0Vk5EcUt0RUVzcFZsaFR0ajhzZ190azhlcTBWLTNueVE0RWZjc1J6djR1ekR6VHlvbTB6bzlSQk1zWU0?oc=5","date":"2023-06-06","type":"deal","source":"Business Wire","summary":"Propanc Biopharma Announces Strategic Pharma Partnering Initiative - Business Wire","headline":"Propanc Biopharma Announces Strategic Pharma Partnering Initiative","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":4},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}